Top 18 newest treatment for multiple myeloma 2020 in 2022

Below are the best information and knowledge on the subject newest treatment for multiple myeloma 2020 compiled and compiled by our own team alltopus:

1. Therapy for Multiple Myeloma Has New Approach With One-Time Treatment

Author: www.uhhospitals.org

Date Submitted: 03/03/2019 01:09 AM

Average star voting: 5 ⭐ ( 15681 reviews)

Summary: The therapy is used when the standard treatment for multiple myeloma – a combination of chemotherapy, radiation therapy and/or stem cell transplant – is no longer effective.

Match with the search results: Therapy for Multiple Myeloma Has New Approach With One-Time Treatment. Patients being treated for multiple myeloma have a promising new option for treatment. The treatment, called …. read more

Therapy for Multiple Myeloma Has New Approach With One-Time Treatment

2. FDA Approves New Treatment Option for Patients with Multiple Myeloma at First or Subsequent Relapse | Leukemia and Lymphoma Society

Author: www.webmd.com

Date Submitted: 03/16/2020 04:34 PM

Average star voting: 4 ⭐ ( 36395 reviews)

Summary:

Match with the search results: Ixazomib (Ninlaro) is the first and only oral proteasome inhibitor that the FDA has approved for multiple myeloma treatment. Proteasomes are ……. read more

FDA Approves New Treatment Option for Patients with Multiple Myeloma at First or Subsequent Relapse | Leukemia and Lymphoma Society

3. Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma | Dana-Farber

Author: www.lls.org

Date Submitted: 09/13/2019 02:12 AM

Average star voting: 3 ⭐ ( 63935 reviews)

Summary: For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects.

Match with the search results: The latest approval is for the combination of daratumumab plus hyaluronidase-fijh (Darzalex Faspro) plus carfilzomib (Kyprolis) and the steroid ……. read more

Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma | Dana-Farber

4. CAR T-Cell Therapy Approved for Multiple Myeloma

Author: www.cancer.net

Date Submitted: 11/28/2020 02:11 PM

Average star voting: 3 ⭐ ( 50150 reviews)

Summary: FDA has approved idecabtagene vicleucel (Abecma) for people with multiple myeloma that hasn’t responded to or has returned after at least four different cancer treatments. The approval is based, in part, on the results of a small study in which ide-cel partially or completely shrank tumors in 72% of patients.

Match with the search results: Daratumumab may be given to treat newly diagnosed multiple myeloma. A drug combination of daratumumab and hyaluronidase-fihj (Darzalex Faspro) with or without ……. read more

CAR T-Cell Therapy Approved for Multiple Myeloma

5. A new era of novel immunotherapies for multiple myeloma

Author: www.hmpgloballearningnetwork.com

Date Submitted: 09/05/2020 06:48 PM

Average star voting: 4 ⭐ ( 73651 reviews)

Summary:

Match with the search results: Daratumumab and hyaluronidase-fihj. Subcutaneous daratumumab (daratumumab and hyaluronidase-fihj) was granted FDA approval in May 2020 for ……. read more

A new era of novel immunotherapies for multiple myeloma

6. Current FDA-Approved Medications

Author: blog.dana-farber.org

Date Submitted: 11/14/2020 12:56 AM

Average star voting: 4 ⭐ ( 79798 reviews)

Summary: This list of current FDA-approved multiple myeloma drugs is organized by drug class, with a guide to the generic and brand names for each medication.

Match with the search results: Option for relapsed or refractory (non-responsive) myeloma · A drug that doesn’t cause hair loss · Drug for patients eligible for stem cell ……. read more

Current FDA-Approved Medications

7. Multiple myeloma current treatment algorithms | Blood Cancer Journal

Author: www.cancer.gov

Date Submitted: 09/27/2020 06:10 AM

Average star voting: 3 ⭐ ( 24219 reviews)

Summary: The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple new drugs, and emerging data from randomized trials to guide therapy. Along the disease course, the choice of specific therapy is affected by many variables including age, performance status, comorbidities, and eligibility for stem cell transplantation. In addition, another key variable that affects treatment strategy is risk stratification of patients into standard and high-risk MM. High-risk MM is defined by the presence of t(4;14), t(14;16), t(14;20), gain 1q, del(17p), or p53 mutation. In this paper, we provide algorithms for the treatment of newly diagnosed and relapsed MM based on the best available evidence. We have relied on data from randomized controlled trials whenever possible, and when appropriate trials to guide therapy are not available, our recommendations reflect best practices based on non-randomized data, and expert opinion. Each algorithm has been designed to facilitate easy decision-making for practicing clinicians. In all patients, clinical trials should be considered first, prior to resorting to the standard of care algorithms we outline.

Match with the search results: FDA has approved idecabtagene vicleucel (Abecma) for people with multiple myeloma that hasn’t responded to or has returned after at least ……. read more

Multiple myeloma current treatment algorithms | Blood Cancer Journal

8. A New Treatment Option for Patients with Multiple Myeloma | OHC

Author: www.nhs.uk

Date Submitted: 10/31/2020 01:35 AM

Average star voting: 5 ⭐ ( 80369 reviews)

Summary: Among the array of multiple myeloma clinical trials at OHC is a trial evaluating a new treatment for RRMM that has demonstrated significant results in initial trials.

Match with the search results: Isatuximab is a new antibody treatment that is used to treat multiple myeloma in adults where 3 other treatments have not worked. It’s taken with pomalidomide ……. read more

A New Treatment Option for Patients with Multiple Myeloma | OHC

9. Emerging agents and regimens for multiple myeloma – Journal of Hematology & Oncology

Author: www.thelancet.com

Date Submitted: 06/20/2021 11:03 AM

Average star voting: 4 ⭐ ( 24601 reviews)

Summary: The outcomes of multiple myeloma (MM) have been improved significantly with the therapies incorporating proteasome inhibitors (PI), immunomodulatory drugs, monoclonal antibodies (MoAb) and stem cell transplantation. However, relapsed and refractory MM (RRMM) remains a major challenge. Novel agents and regimens are under active clinical development. These include new PIs such as ixazomib, marizomib, and oprozomib; new MoAbs such as isatuximab and MOR202; novel epigenetic agent ricolinostat and novel cytokines such as siltuximab. Recently, the first XPO-1 inhibitor, selinexor, was approved for RRMM. BCMA-targeted BiTE, antibody–drug conjugates and CAR-T cells have the potential to revolutionize the therapy for RRMM. In this review, we summarized the latest clinical development of these novel agents and regimens.

Match with the search results: Teclistamab is a novel treatment approach for relapsed or refractory multiple myeloma. At the recommended phase 2 dose, teclistamab showed ……. read more

Emerging agents and regimens for multiple myeloma - Journal of Hematology & Oncology

10. FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma

Author: www.myeloma.org

Date Submitted: 12/26/2020 05:50 PM

Average star voting: 5 ⭐ ( 82092 reviews)

Summary: FDA approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor

Match with the search results: Xpovio (selinexor), a new medication to treat myeloma, is a “nuclear export inhibitor,” the first compound in this new drug class. Nuclear export inhibitors ……. read more

FDA Approves New Therapy for Patients with Previously Treated Multiple Myeloma

11. Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020

Author: www.nature.com

Date Submitted: 06/29/2021 12:39 AM

Average star voting: 5 ⭐ ( 62658 reviews)

Summary:

Match with the search results: Therapy for Multiple Myeloma Has New Approach With One-Time Treatment. Patients being treated for multiple myeloma have a promising new option for treatment. The treatment, called …. read more

Major advances in the treatment of multiple myeloma in American Society of Hematology annual meeting 2020

12. Drug Therapy for Multiple Myeloma

Author: themmrf.org

Date Submitted: 02/19/2020 11:27 AM

Average star voting: 3 ⭐ ( 48276 reviews)

Summary: Many different types of drugs can be used to treat multiple myeloma. Learn more about them here.

Match with the search results: Ixazomib (Ninlaro) is the first and only oral proteasome inhibitor that the FDA has approved for multiple myeloma treatment. Proteasomes are ……. read more

Drug Therapy for Multiple Myeloma

13. Newly Diagnosed Myeloma in 2020

Author: ohcare.com

Date Submitted: 11/26/2021 12:08 PM

Average star voting: 4 ⭐ ( 46996 reviews)

Summary:

Match with the search results: The latest approval is for the combination of daratumumab plus hyaluronidase-fijh (Darzalex Faspro) plus carfilzomib (Kyprolis) and the steroid ……. read more

Newly Diagnosed Myeloma in 2020

14. Multiple myeloma: the (r)evolution of current therapy and a glance into future | Haematologica

Author: jhoonline.biomedcentral.com

Date Submitted: 08/09/2021 03:54 PM

Average star voting: 5 ⭐ ( 90848 reviews)

Summary:

Match with the search results: Daratumumab may be given to treat newly diagnosed multiple myeloma. A drug combination of daratumumab and hyaluronidase-fihj (Darzalex Faspro) with or without ……. read more

Multiple myeloma: the (r)evolution of current therapy and a glance into future | Haematologica

15. Reversing Treatment Resistance in Advanced Multiple Myeloma : Oncology Times

Author: www.fda.gov

Date Submitted: 05/12/2020 05:10 PM

Average star voting: 5 ⭐ ( 74634 reviews)

Summary:

Match with the search results: Daratumumab and hyaluronidase-fihj. Subcutaneous daratumumab (daratumumab and hyaluronidase-fihj) was granted FDA approval in May 2020 for ……. read more

Reversing Treatment Resistance in Advanced Multiple Myeloma : Oncology Times

16. Multiple Myeloma | New Cancer Drug Could Help People

Author: www.sciencedirect.com

Date Submitted: 02/07/2021 04:47 PM

Average star voting: 5 ⭐ ( 81552 reviews)

Summary: Dr Tuna Mutis has been studying a new drug for the blood cancer multiple myeloma. His new discovery will help start new cures for cancer.

Match with the search results: Option for relapsed or refractory (non-responsive) myeloma · A drug that doesn’t cause hair loss · Drug for patients eligible for stem cell ……. read more

Multiple Myeloma | New Cancer Drug Could Help People

17. Multiple myeloma: the (r)evolution of current therapy and a glance into the future

Author: www.cancer.org

Date Submitted: 05/28/2019 07:12 AM

Average star voting: 4 ⭐ ( 52426 reviews)

Summary:

Match with the search results: FDA has approved idecabtagene vicleucel (Abecma) for people with multiple myeloma that hasn’t responded to or has returned after at least ……. read more

Multiple myeloma: the (r)evolution of current therapy and a glance into the future

18. Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma

Author: www.cancer.org

Date Submitted: 08/01/2020 12:26 PM

Average star voting: 3 ⭐ ( 84835 reviews)

Summary: The FDA approval of the first chimeric antigen receptor T-cell therapy in March 2021 for the treatment of relapsed/refractory multiple myeloma represents a significant advance.

Match with the search results: Isatuximab is a new antibody treatment that is used to treat multiple myeloma in adults where 3 other treatments have not worked. It’s taken with pomalidomide ……. read more

Cellular Therapy Strategies Offer the Prospect of Deep Remissions for Multiple Myeloma

Related Posts

Leave a Reply

Your email address will not be published.